LT2001093A - Interferono alfa farmacinė kompozicija - Google Patents
Interferono alfa farmacinė kompozicijaInfo
- Publication number
- LT2001093A LT2001093A LT2001093A LT2001093A LT2001093A LT 2001093 A LT2001093 A LT 2001093A LT 2001093 A LT2001093 A LT 2001093A LT 2001093 A LT2001093 A LT 2001093A LT 2001093 A LT2001093 A LT 2001093A
- Authority
- LT
- Lithuania
- Prior art keywords
- ifn
- pharmaceutical composition
- manufacture
- aqueous solution
- interferon alfa
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108010078049 Interferon alpha-2 Proteins 0.000 abstract 5
- 229960003507 interferon alfa-2b Drugs 0.000 abstract 5
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 abstract 5
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 239000001509 sodium citrate Substances 0.000 abstract 1
- 235000011083 sodium citrates Nutrition 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 abstract 1
- 229940033663 thimerosal Drugs 0.000 abstract 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Išradimas aprašo interferono alfa-2 (IFN) tirpalą, kuris pasižymi padidintu terminiu stabilumu ir atsparumu autooksidacijai bei jo paruošimo būdą. Tirpalas turi (0,01-50) x 106 TV/ml interferono alfa-2b, 0,08-0,1 M natrio citratų, 0,05-0,06 M glicino, 0,008-0,01 % polisorbato-20, 0,004-0,005 % timerosalio. Tirpalo pH palaikomas 6,0±0,1. Išradimas priklauso farmacijos sričiai ir gali būti panaudotas IFN skystų vaistinių formų, skirtų kai kurių virusinių ir onkologinių ligų terapijai, gamyboje ir biotechnologijoje genoinžinerinio IFN gamybos procesuose.ą
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT2001093A LT4947B (lt) | 2001-09-26 | 2001-09-26 | Interferono alfa farmacinė kompozicija |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT2001093A LT4947B (lt) | 2001-09-26 | 2001-09-26 | Interferono alfa farmacinė kompozicija |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2001093A true LT2001093A (lt) | 2002-04-25 |
| LT4947B LT4947B (lt) | 2002-08-26 |
Family
ID=19721558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2001093A LT4947B (lt) | 2001-09-26 | 2001-09-26 | Interferono alfa farmacinė kompozicija |
Country Status (1)
| Country | Link |
|---|---|
| LT (1) | LT4947B (lt) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61277633A (ja) | 1985-05-31 | 1986-12-08 | Toray Ind Inc | インタ−フエロン組成物 |
| IL88233A (en) | 1987-11-03 | 1993-08-18 | Genentech Inc | Gamma interferon formulation |
| US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
-
2001
- 2001-09-26 LT LT2001093A patent/LT4947B/lt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| LT4947B (lt) | 2002-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE84799A1 (es) | Metodos mejorados para el procesamiento de proteina c activada | |
| ATE245033T1 (de) | Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen | |
| SG52690A1 (en) | Process for the production of biologically active protein (e.g. tgf) | |
| BR0316407A (pt) | Derivados de nucleosìdeo antiviral | |
| SE9701398D0 (sv) | Novel compounds | |
| DE69838986D1 (de) | Polypeptide, deren herstellung und verwendung | |
| BR9814276A (pt) | Antìgenos de superfìcie | |
| DE69434980D1 (de) | Stabile bakterizide Proteine, welche die Permeabilität erhöhen und pharmazeutische Zusammensetzungen, diese enthaltend | |
| BR9908015A (pt) | Composições que compreendem vìrus e métodos para concentração de preparações de vìrus | |
| BRPI0412241A (pt) | formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa) | |
| AP2000001860A0 (en) | Hypolipidemic benzothiazepine compounds. | |
| MY129422A (en) | Medicinal compounds | |
| IL101836A0 (en) | Pharmaceutical compositions containing 1,3-oxathiolane nucleoside derivatives | |
| HUP0002247A2 (hu) | Proteáz inhibitorok | |
| ZA865192B (en) | New carboxylic acid derivatives,processes for the preparation thereof,the use thereof and pharmaceutical compositions containing them | |
| FI945975A0 (fi) | Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia | |
| ATE215817T1 (de) | Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis | |
| DZ2681A1 (fr) | Forme nouvelle d'hydrate de sel d'acide maléique de 5-Ä4-Ä2-(n-methyl-n(2-pyridyl)amino)ethoxyÜbenzylÜ-thiazololidine-2,4-dione et composition pharmaceutique la contenant. | |
| HUP9802206A1 (hu) | Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához | |
| ATE107859T1 (de) | Verwendung von antiprogestomimetika zur stimulierung des eisprungs. | |
| AR042019A1 (es) | N-acetilgalactosamina-4-sulfatasa precursora, composiciones farmaceuticas que la contienen , metodos de tratamiento que la utilizan y metodos para producirla y purificarla | |
| NO993407L (no) | Fremstilling av proteinpreparater med nedsatt aggregatinnhold | |
| EE200200326A (et) | Asendatud homopiperidüülbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon | |
| ATE371737T1 (de) | Proteaseresistente flint-analoge | |
| TR199900523T2 (xx) | Vir�s k�kenli hastal�klar�n tedavisi i�in farmas�tik bile�imler. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 20040926 |